Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?

Autor:	Bernasko N; Department of Medicine, Penn State Hershey Medical Center, Division of Gastroenterology and Hepatology, Hershey, Pennsylvania, USA., Clarke K; Department of Medicine, Penn State Hershey Medical Center, Division of Gastroenterology and Hepatology, Hershey, Pennsylvania, USA.
Jazyk:	angličtina
Zdroj:	Crohn's & colitis 360 [Crohns Colitis 360] 2021 Mar 27; Vol. 3 (4), pp. otab004. Date of Electronic Publication: 2021 Mar 27 (Print Publication: 2021).
DOI:	10.1093/crocol/otab004
Abstrakt:	Aim: To assess knowledge, practice patterns and attitudes toward the use of biosimilars by Advanced Practice Providers (APPs) treating patients with inflammatory bowel disease (IBD). Background: APPs provide care in a variety of healthcare settings including medical specialties. In Gastroenterology, they are an integral part of providing care to a complex group of patients with IBD. There has been an increase in options of medical therapies for treating IBD. These include small molecules, biologics, and biosimilars. Adoption of biosimilars for treatment of IBD patients by gastroenterologists in the United States compared to Europe has been slow for several reasons. There is lack of data on their use by APPs who provide frontline IBD clinical care in the United States. Methods: Questionnaire-based survey of APPs attending Gastroenterology conferences with a focus on IBD. Results: APPs in gastroenterology do not routinely consider the use of biosimilars in their practice. Conclusions: There is low utilization of biosimilars in treating IBD patients by APPs. In addition, there are significant concerns about risk of side effects as well as perceived lack of APP targeted educational resources. (© The Author(s) 2021. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu